The SPOTLIGHT trial is a multicenter, randomized, double-blind, phase III trial designed to evaluate zolbetuximab plus mFOLFOX6 superiority over standard chemotherapy (mFOLFOX6) in the primary treatment of CLDN18.2-positive, HER2-negative gastric and GEJ adenocarcinomas with unresectable locally advanced or metastatic disease [8]. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.